Back grey_arrow_rt.gif
 
 
Dolutegravir (DTG; S/GSK1349572) + Abacavir/Lamivudine Once Daily Statistically Superior to Tenofovir/Emtricitabine/Efavirenz: 48-Week Results - SINGLE (ING114467) - ViiV Healthcare ICAAC Media Statement
 
 
  ICAAC - late-breaker abstract. Monday, Sep 10, 2012, 10:30 AM - 10:45 AM

S. Walmsley, A. Antela, N. Clumeck, D. Duiculescu, A. Eberhard, F. Gutierrez, L. Hocqueloux, F. Maggiolo, Sandkovsky, C. Granier, B. Wynne, K. Pappa

STATEMENT: Shionogi-ViiV Healthcare LLC today presented full 48-week data from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in HIV-1 treatment-naïve adults. Headline data from the SINGLE study was announced on 11 July 2012 and superiority of the dolutegravir-based regimen compared to Atripla® was concluded as part of a pre-specified testing procedure; differences in efficacy were primarily driven by the lower rate of discontinuation due to adverse events on the dolutegravir arm.

Full SINGLE study data presented at the 52nd International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco demonstrates that important additional endpoints including resistance, rapidity of antiviral response and CD4 cell recovery also favoured dolutegravir vs Atripla;

· Resistance: no subject in the dolutegravir + ABC/3TC arm had treatment-emergent integrase inhibitor resistance mutations or NRTI resistance mutations, whereas 1 subject in the Atripla group developed NRTI resistance mutations and 4 developed NNRTI resistance mutations

· Median time to undetectable viral load: 28 days on DTG arm vs 84 days on Atripla arm [p<0.0001]

· Change from baseline CD4 cells/mm3: +267 on DTG arm vs +208 on Atripla arm [p<0.001].

The three most common adverse events reported by patients on the Atripla regimen were dizziness (35%), diarrhea (18%) and abnormal dreams (17%), while patients on the dolutegravir-based regimen reported diarrhea (18%), nasopharyngitis (15%), and insomnia (15%). Neuropsychiatric events and rash events occurred significantly more often among Atripla recipients than those receiving DTG+ABC/3TC.

About SINGLE (ING114467)

SINGLE is an ongoing Phase III, randomised, multi-centre, multinational, double-blind, double dummy study designed to compare the efficacy and safety of two antiretroviral regimens: dolutegravir 50mg plus abacavir/lamivudine (Kivexa®/Epzicom®) versus Atripla (tenofovir/emtricitabine/efavirenz). The primary endpoint was the proportion of study participants with undetectable HIV-1 RNA (<50c/mL) at 48 weeks; 414 treatment-naïve study participants were randomised and exposed to the dolutegravir-based regimen and 419 to the Atripla arm.

Headline data from the clinical trial SINGLE were announced in July 2012. The SINGLE study was designed to demonstrate non-inferiority of the dolutegravir-based regimen versus Atripla, and the primary analysis met this criterion. Superiority of the dolutegravir-based regimen compared to Atripla was concluded as part of a pre-specified testing procedure

About Dolutegravir and the Dolutegravir Clinical Trial Programme

S/GSK1349572 (dolutegravir) is an investigational integrase inhibitor currently in development by Shionogi-ViiV Healthcare LLC for the treatment of HIV. Dolutegravir does not require an additional 'booster' drug be added to the regimen. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection. Given the stage of development of this investigational HIV therapy, the full picture of the efficacy and safety of dolutegravir has not been conclusively determined.

SINGLE is the second of four Phase III studies that are due to be reported in 2012. Full data from the clinical trial SPRING-2 (ING113086) were announced in July 2012. Data from VIKING-3 (ING112574) and SAILING (ING111762) in treatment-experienced patients is expected to report in house in 2H 2012 and will allow further characterisation of the profile of dolutegravir. These studies are designed to support a future regulatory filing for dolutegravir.

About Shionogi-ViiV Healthcare LLC

The Shionogi-ViiV Healthcare LLC is a joint venture between Shionogi & Co., Ltd. and ViiV Healthcare Ltd., a global company with a sole focus on HIV established in 2009 by GlaxoSmithKline and Pfizer, Inc. Dolutegravir is the lead compound in the Shionogi-ViiV Healthcare LLC partnership. Shionogi-ViiV Healthcare LLC is also developing another integrase inhibitor which is at an earlier stage of development.

About Shionogi & Co., Ltd

Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company is the originator of innovative medicines which have been successfully delivered to millions of patients worldwide. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi, Inc. headquartered in Florham Park, NJ, please visit www.shionogi.com.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.

091312-7.gif

Shionogi forward-looking statement: This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. This announcement contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations nor provide medical advice of any kinds.

GlaxoSmithKline cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

Pfizer disclosure notice: Pfizer assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments. This release contains forward-looking information about Pfizer, GlaxoSmithKline and ViiV Healthcare and about the prospects of the companies, including revenues from in-line products and the potential benefits of product candidates that will be contributed to that company, as well as the potential financial impact of the transaction. Such information involves substantial risks and uncertainties including, among other things, decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates; and competitive developments.

A further list and description of risks and uncertainties can be found in Pfizer's Annual Report of Form 10-K for the fiscal year ended December 31, 2011 and in its reports on Form 10-Q and Form 8-K.

 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org